Biogen is executing a multi-year pivot from a declining MS franchise toward neurology growth products (LEQEMBI, SKYCLARYS, ZURZUVAE, QALSODY) and an expanding immunology/nephrology pipeline via the HI-Bio ($1.15B) and Apellis ($5.6B) acquisitions. At ~11x FY2026E non-GAAP EPS, the market prices the legacy decline but undervalues the pipeline optionality from felzartamab (3 Phase 3 kidney disease programs) and the LEQEMBI subcutaneous franchise expansion. The key question is whether growth product ramp and pipeline readouts can offset the structural MS revenue erosion and biosimilar risk on Tysabri before 2028.
| Scenario | Prob. | Target | Driver |
|---|---|---|---|
| Bull | 25% | $275.00 | LEQEMBI IQLIK subcutaneous initiation approved (PDUFA extended to August 24, 2026) — accelerates patient uptake |
| Base | 50% | $205.00 | Company executes on FY2026 guidance: mid-single digit revenue decline, $15.25-$16.25 non-GAAP EPS |
| Bear | 25% | $130.00 | LEQEMBI uptake stalls — Eli Lilly Kisunla takes majority share, trontinemab Phase 3 data looks superior |
Research-update [source: ]
Initial /complete-research coverage + Phase B competitive deep dive
None mapped.
Positioning skews toward near-term upside